Latest

Trackers› Clinical trials› Zhengzhou

Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC

19052

Studies in scope

all four open statuses

11786

Recruiting now

open to new participants

2009

Lead sponsors

across recruiting studies

Top sites

Beijing 65 Guangzhou 54 Wuhan 33 Shanghai 28 Nanjing 25

Narrow the registerReset

Search within results

Recruitment status

Phase

Lead sponsor

Clear sponsor filter

Site location

All 65 locations

Target enrolment

to

Trials with a site in Zhengzhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Recruiting

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Novartis Pharmaceuticals

Phase 2

50

Zhengzhou, Tianjin

2026-04-28

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

Novartis Pharmaceuticals

Phase 3

1,275

Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan

2025-11-11

Recruiting

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease

Novartis Pharmaceuticals

Phase 4

50

Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing

2025-09-09

Active, closed

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

NCT06941792Coronary Heart Disease

Novartis Pharmaceuticals

Phase 4

1,590

Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang

2025-06-17

Recruiting

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

NCT06931691Paroxysmal Nocturnal Hemoglobinuria

Novartis Pharmaceuticals

Observational

80

Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun

2025-06-10

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

Novartis Pharmaceuticals

Phase 3

180

Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing

2025-02-07

Recruiting

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

Novartis Pharmaceuticals

Phase 2

200

Nanning, Zhengzhou, Changchun, Chengdu, Ningbo, Beijing, Tianjin

2024-10-09

Active, closed

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

Novartis Pharmaceuticals

Phase 2

84

Shijiazhuang, Zhengzhou, Beijing

2024-08-05

Active, closed

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

NCT06372925Plaque, Atherosclerotic

Novartis Pharmaceuticals

Phase 4

318

Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan

2024-07-09

Active, closed

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT06462469Steroid-refractory Acute Graft Versus Host Disease

Novartis Pharmaceuticals

Phase 4

36

Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin

2024-07-04

Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

Novartis Pharmaceuticals

Phase 3

1,400

Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan

2024-02-28

Active, closed

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349Primary Immune Thrombocytopenia (ITP)

Novartis Pharmaceuticals

Phase 3

226

Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang

2023-02-03

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Novartis Pharmaceuticals

Phase 4

347

Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing

2022-08-30

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

NCT05147220Relapsing Multiple Sclerosis

Novartis Pharmaceuticals

Phase 3

1,000

Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing

2021-12-16

Active, closed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052Differentiated Thyroid Cancer (DTC)

Novartis Pharmaceuticals

Phase 3

153

Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu

2021-11-15

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Novartis Pharmaceuticals

Phase 3

405

Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu

2021-10-06

Active, closed

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

Novartis Pharmaceuticals

Phase 3

448

Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan

2021-09-20

Active, closed

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

NCT04544189Breast Neoplasms

Novartis Pharmaceuticals

Phase 2

69

Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing

2021-01-20

Active, closed

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

NCT04666272Melanoma

Novartis Pharmaceuticals

Observational

78

Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing

2020-12-31

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

Novartis Pharmaceuticals

Phase 3

5,101

Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun

2018-12-07

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

8 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 20 studies
Phase	Studies	Recruiting	Share
Phase 3	9	3	45%
Phase 4	5	2	25%
Phase 2	4	2	20%
Observational	2	1	10%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsor	Studies	Recruiting
Novartis Pharmaceuticals	20	8

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.